Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Completes HCV Clinical Development With Vosevi Approval

Jul 18 2017

• By Joseph Haas

Related Content

Direct-Acting Antivirals Slapped With Black Box On Hepatitis B Risk

Oct 04 2016

AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU

Jun 21 2017

Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Nov 24 2016

Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues

May 03 2017

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Nov 02 2016

Related Companies

Gilead Sciences, Inc.

Merck & Co., Inc.

AbbVie Inc.

Additional Topics

Approvals Companies Commercial Infectious Diseases BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.